# Pathophysiological Role of Vitamin D Deficiency in Down Syndrome: Insights into Metabolic Dysfunction and Sarcopenia

**Authors:** Maria Stella Valle, Cristina Russo, Sofia Surdo, Maria Teresa Cambria, Mariachiara Campanella, Michele Tuttobene, Lucia Malaguarnera

PMC · DOI: 10.3390/ijms262110756 · 2025-11-05

## TL;DR

This paper explores how vitamin D deficiency contributes to metabolic and muscle problems in people with Down syndrome and suggests it could be a key target for treatment.

## Contribution

The paper provides a comprehensive review of vitamin D's role in metabolic dysfunction and sarcopenia specific to Down syndrome.

## Key findings

- Vitamin D deficiency is linked to metabolic syndrome, insulin resistance, and muscle weakness in Down syndrome.
- Vitamin D regulates immune responses, metabolic balance, and muscle performance in individuals with Down syndrome.
- Vitamin D is proposed as a potential biomarker and therapeutic target for improving health outcomes in this population.

## Abstract

People with Down syndrome represent a highly vulnerable population, frequently showing vitamin D deficiency together with an elevated risk of metabolic and neuromuscular dysfunction. This susceptibility derives from several factors, including muscular hypotonia, excess body weight, thyroid abnormalities, and immune dysregulation. The coexistence of these conditions compromises bone and muscle health, increases cardiometabolic risk, and reduces motor abilities and coordination, thereby predisposing individuals to falls, sarcopenia, sarcopenic obesity, and long-term disability. Vitamin D, traditionally known for its essential role in bone health, is now recognized as a pleiotropic hormone regulating immune responses, metabolic balance, and muscle performance. Its deficiency is increasingly linked to obesity, insulin resistance, diabetes mellitus, dyslipidemia, and metabolic syndrome. These adverse outcomes are mediated through mechanisms involving chronic inflammation, oxidative stress, mitochondrial impairment, and disrupted adipokine signaling. This review integrates current molecular, cellular, and clinical evidence on the multifaceted actions of vitamin D in Down syndrome. Particular emphasis is placed on its effects on insulin signaling, adipose tissue metabolism, inflammatory regulation, and muscle strength. Finally, vitamin D is discussed as a biomarker and therapeutic target to guide personalized interventions aimed at improving metabolic health, maintaining muscle function, and promoting long-term independence in this high-risk population.

## Linked entities

- **Diseases:** Down syndrome (MONDO:0008608), metabolic syndrome (MONDO:0000816), diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** thyroid abnormalities (MESH:D013959), obesity (MESH:D009765), metabolic syndrome (MESH:D024821), muscular hypotonia (MESH:D009123), mitochondrial impairment (MESH:D028361), inflammation (MESH:D007249), falls (MESH:C537863), insulin resistance (MESH:D007333), immune dysregulation (OMIM:614878), diabetes mellitus (MESH:D003920), long-term disability (MESH:D000088562), dyslipidemia (MESH:D050171), Metabolic Dysfunction (MESH:D008659), Sarcopenia (MESH:D055948), metabolic and neuromuscular dysfunction (MESH:D009468), Down Syndrome (MESH:D004314), Vitamin D Deficiency (MESH:D014808)
- **Chemicals:** Vitamin D (MESH:D014807)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12610304/full.md

---
Source: https://tomesphere.com/paper/PMC12610304